Articles by tag: lecanemab

Subcutaneous Lecanemab: FDA Priority Status 2026

FDA extended review of subcutaneous Lecanemab for therapy initiation. Learn about the new standard of home Alzheimer's treatment and approval forecasts.

FDA will approve subcutaneous Lecanemab in August 2026

Analysis of the FDA decision postponement for Leqembi IQLIK to August 24: why this is a signal for approval, not a delay. Benefits for Alzheimer's patients and market forecast. Read key takeaways.

Lecanemab in Alzheimer's disease: 27% slowing

Lecanemab is the first drug with full FDA approval that slows cognitive decline by 27%. Learn about efficacy, risks, and therapy availability.